IMNN Company Profile and Key Details

Imunon, Inc. (NASDAQ:IMNN) closed at $1.47 USD, gaining $0.02 (1.38%) from the previous close of $1.45. The stock is currently mid-range between its 52-week high and low $1.39 and $5.85. With a market capitalization of about $6.18 million, Imunon, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.98). Key stats such as the average daily volume over the past year has been around 141.24 thousand shares, in line with its 52-week average. Headquartered in Lawrenceville, NJ, Imunon, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Stacy R. Lindborg, the company employs approximately 20 people and listed since March 01, 1999. Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies.

Imunon, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.66. This means the shares are trading below this model’s fair value.

Short-term trend indicators are bullishly aligned (SMA20 -2.3%, SMA50 -9.65%, SMA200 -53.47%). The stock’s 14-day RSI is 40.41 (neutral), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -92.33% below its high and over 5.69% above its low. Average 10-day trading volume of 196.50 thousand shares is slightly above the 3-month average of 140.77 thousand, indicating heightened recent market interest.

Imunon, Inc. has 2.52 million shares outstanding. The public float is 2.49 million shares, elevated short interest at 11.27% of float. This equals 273.05 thousand shares. The short ratio is 0.63 days. Institutional investors hold 12.68% of the float. Insiders own 5.45%. EGWU, Inc. fka EGEN, Inc. holds 2.42 million shares, Tardugno Michael H has 353.35 thousand shares and Lindborg Stacy has 264.17 thousand shares. Over the past six months, insider transactions show net selling. They sold 22.38 thousand shares across 6 transactions.

Imunon, Inc. generated EPS of -$10.36 over the past year. Five-year average earnings growth is 32.54%. Wall Street analysts project EPS growth of 59.15% annually over the next five years. The latest quarter delivered EPS of -$0.54. The next quarter is forecast at -$1.01. Next year's EPS is expected at $12.54. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $10.00. The high target offers 580.27% upside. The low target suggests 580.27% downside. The mean target is $10.00. This offers 580.27% upside. Imunon, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended August 11, 2026, missed forecasts by -37.75%. The prior quarter beat by -30.86%. Over the last six quarters, Apple has recorded several small beats. These include -19.96% in May 12, 2025.

Imunon, Inc. (NASDAQ:IMNN) shares are flat -9.19% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Imunon, Inc. trading at a premium to the broader market with a P/E of -0.32. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $19.83, suggesting 1248.98% upside. Our AI forecast model points to short-term weakness (-4.76% over two weeks), a medium-term fall (-27.21% over three months), and a longer-term loss (-65.31% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Imunon, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.76%, with price expected at $1.40 by September 25, 2026, within a range of $1.36 to $1.43 3-Month Outlook: Projected fall of -27.21%, reaching $1.07 by December 10, 2026, with a range of $0.27 to $1.33. 1-Year Outlook: Projected loss of -65.31%, with price at $0.51 by September 10, 2027, within a range of $0.00 to $0.28.

Imunon, Inc. trades at a P/E ratio of -0.32, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.84 suggesting the stock is closer to book value. The P/FCF stands at -0.0, also above market averages.